Oral Exposure to Clostridium difficile Toxin A Aggravates Food Allergy by Intestinal Barrier Destruction, Mast Cell Activation, and Th2-Biased Immune Responses., PMID:39847683
Structural insight into recognition of Clostridioides difficile toxin A by novel neutralizing nanobodies targeting QTIN-like motifs within its receptor-binding domain., PMID:39577542
Development of two recombinant vaccines against Clostridioides difficile infection and immunogenicity in pregnant sows and neonatal piglets., PMID:39127403
Monoclonal antibody-mediated neutralization of Clostridioides difficile toxin does not diminish induction of the protective innate immune response to infection., PMID:38701911
A fine-tuned yeast surface-display/secretion platform enables the rapid discovery of neutralizing antibodies against Clostridioides difficile toxins., PMID:37749574
Establishment of a Novel Detection Platform for Clostridioides difficile Toxin Genes Based on Orthogonal CRISPR., PMID:37378559
Corrigendum: Structure-guided design of a potent Clostridioides difficile toxin A inhibitor., PMID:37065148
Neutralizing epitopes on Clostridioides difficile toxin A revealed by the structures of two camelid VHH antibodies., PMID:36466927
Facile Affinity Maturation of Single-Domain Antibodies Using Next-Generation DNA Sequencing., PMID:35157277
Fecal Microbiota Transplantation for Recurrent Clostridioides difficile Infection Enhances Adaptive Immunity to C difficile Toxin B., PMID:33444574
Phylogenomics of 8,839 Clostridioides difficile genomes reveals recombination-driven evolution and diversification of toxin A and B., PMID:33370413
Absence of Toxemia in Clostridioides difficile Infection: Results from Ultrasensitive Toxin Assay of Serum., PMID:33164145
Efficacy and Safety of Monoclonal Antibodies Against Clostridioides difficile Toxins for Prevention of Recurrent Clostridioides difficile Infection: A Systematic Review and Meta-Analysis., PMID:32053529
Therapeutic Mechanism of Macrophage Inflammatory Protein 1 α Neutralizing Antibody (CCL3) in Clostridium difficile Infection in Mice., PMID:31793629
Development of a new serological assay for the diagnosis of Clostridium difficile infections with prognostic value., PMID:31733265
Proteomic profiling of precipitated Clostridioides difficile toxin A and B antibodies., PMID:31718902
Rapid Detection of Clostridium difficile Toxins in Stool by Raman Spectroscopy., PMID:31279995
Vaccination against Clostridium difficile by Use of an Attenuated Salmonella enterica Serovar Typhimurium Vector (YS1646) Protects Mice from Lethal Challenge., PMID:31138615
Treatment and Prevention of Recurrent Clostridium difficile Infection with Functionalized Bovine Antibody-Enriched Whey in a Hamster Primary Infection Model., PMID:30736358
Difference in Mono-O-Glucosylation of Ras Subtype GTPases Between Toxin A and Toxin B From Clostridioides difficile Strain 10463 and Lethal Toxin From Clostridium sordellii Strain 6018., PMID:30622517
Clostridium difficile Toxoid Vaccine Candidate Confers Broad Protection against a Range of Prevalent Circulating Strains in a Nonclinical Setting., PMID:29632249
Actoxumab + bezlotoxumab combination: what promise for Clostridium difficile treatment?, PMID:29534621
Application of Assisted Design of Antibody and Protein Therapeutics (ADAPT) improves efficacy of a Clostridium difficile toxin A single-domain antibody., PMID:29396522
Adaptive immune response to Clostridium difficile infection: A perspective for prevention and therapy., PMID:29272036
A neutralizing antibody that blocks delivery of the enzymatic cargo of Clostridium difficile toxin TcdB into host cells., PMID:29180448
Use of a neutralizing antibody helps identify structural features critical for binding of Clostridium difficile toxin TcdA to the host cell surface., PMID:28705932
Epitopes and Mechanism of Action of the Clostridium difficile Toxin A-Neutralizing Antibody Actoxumab., PMID:28232034
Mucosal Antibodies to the C Terminus of Toxin A Prevent Colonization of Clostridium difficile., PMID:28167669
Development of a Novel Vaccine Containing Binary Toxin for the Prevention of Clostridium difficile Disease with Enhanced Efficacy against NAP1 Strains., PMID:28125650
Clostridium difficile Toxin A Undergoes Clathrin-Independent, PACSIN2-Dependent Endocytosis., PMID:27942025
Colon-Targeted Delivery of IgY Against Clostridium difficile Toxin A and B by Encapsulation in Chitosan-Ca Pectinate Microbeads., PMID:27826799
A DNA vaccine targeting TcdA and TcdB induces protective immunity against Clostridium difficile., PMID:27770789
Disease Progression and Resolution in Rodent Models of Clostridium difficile Infection and Impact of Antitoxin Antibodies and Vancomycin., PMID:27527088
Intravenous adenovirus expressing a multi-specific, single-domain antibody neutralizing TcdA and TcdB protects mice from Clostridium difficile infection., PMID:27502696
Site-specific phosphorylation and microtubule dynamics control Pyrin inflammasome activation., PMID:27482109
A Tetraspecific VHH-Based Neutralizing Antibody Modifies Disease Outcome in Three Animal Models of Clostridium difficile Infection., PMID:27413067
Novel Clostridium difficile Anti-Toxin (TcdA and TcdB) Humanized Monoclonal Antibodies Demonstrate In Vitro Neutralization across a Broad Spectrum of Clinical Strains and In Vivo Potency in a Hamster Spore Challenge Model., PMID:27336843
Production and Characterization of Chemically Inactivated Genetically Engineered Clostridium difficile Toxoids., PMID:27233688
Safety, immunogenicity and dose response of VLA84, a new vaccine candidate against Clostridium difficile, in healthy volunteers., PMID:27079932
Sensitive assays enable detection of serum IgG antibodies against Clostridium difficile toxin A and toxin B in healthy subjects and patients with Clostridium difficile infection., PMID:26964649
Biochemical and Immunological Characterization of Truncated Fragments of the Receptor-Binding Domains of C. difficile Toxin A., PMID:26271033
Recombinant lipoprotein-based vaccine candidates against C. difficile infections., PMID:26245825
Profiling Humoral Immune Responses to Clostridium difficile-Specific Antigens by Protein Microarray Analysis., PMID:26178385
A chimeric protein comprising the glucosyltransferase and cysteine proteinase domains of toxin B and the receptor binding domain of toxin A induces protective immunity against Clostridium difficile infection in mice and hamsters., PMID:26036797
A Combination of Three Fully Human Toxin A- and Toxin B-Specific Monoclonal Antibodies Protects against Challenge with Highly Virulent Epidemic Strains of Clostridium difficile in the Hamster Model., PMID:25924765
Identification of toxemia in patients with Clostridium difficile infection., PMID:25885671
Development of microbeads of chicken yolk antibodies against Clostridium difficile toxin A for colonic-specific delivery., PMID:25799315
Masking autoprocessing of Clostridium difficile toxin A by the C-terminus combined repetitive oligo peptides., PMID:25725153
The recombinant Lactococcus lactis oral vaccine induces protection against C. difficile spore challenge in a mouse model., PMID:25698490
Mechanisms of protection against Clostridium difficile infection by the monoclonal antitoxin antibodies actoxumab and bezlotoxumab., PMID:25486992
For research use only. Not for human or drug use.
